Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001731122-24-000730
Filing Date
2024-05-06
Accepted
2024-05-06 06:01:40
Documents
7
Period of Report
2024-05-06

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A e5638_def14a.htm DEF 14A 571392
2 GRAPHIC image_001.jpg GRAPHIC 4198
3 GRAPHIC image_001.gif GRAPHIC 5620
4 GRAPHIC image_002.gif GRAPHIC 4943
5 GRAPHIC image_003.gif GRAPHIC 5180
6 GRAPHIC img_005.jpg GRAPHIC 434147
7 GRAPHIC img_006.jpg GRAPHIC 488007
  Complete submission text file 0001731122-24-000730.txt   1870710
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37606 | Film No.: 24915384
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)